New stroke drug shows promise in early trial

NCT ID NCT05403866

Completed Disease control Sponsor: Lumosa Therapeutics Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This Phase 2 trial tested a drug called LT3001 in 89 people who had an acute ischemic stroke. Participants received either the drug or a placebo within 24 hours of their stroke. The study found no serious drug-related side effects, suggesting LT3001 is safe. Researchers are now looking at whether it helps patients recover better than standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LT3001 (a drug given by IV infusion to treat stroke)
What this could lead to: If successful, LT3001 could offer a new treatment option for acute ischemic stroke, potentially improving recovery when given within 24 hours of symptoms.
What could go wrong: This is an early Phase 2 trial with only 89 participants, so results may not apply to all stroke patients. The drug's effectiveness is still unproven, and larger studies are needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE

Contacts and locations

Locations

Chattanooga Center for Neurologic Research

Chattanooga, Tennessee, 37403, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.